Susquehanna International Group
ADIL

Susquehanna International Group’s Adial Pharmaceuticals ADIL Stock Holding History

Susquehanna International Group’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-52
Closed -$88K – 12884
2021
Q4 		$88K Sell
52
-32
-38% -$63K ﹤0.01% 12220
2021
Q3 		$224K Buy
+84
New +$176K ﹤0.01% 11229

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RWML
RAFFA WEALTH MANAGEMENT, LLC Washington, District of Columbia $793M AUM 13.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Susquehanna International Group's ADIL Position: Q1 2026 in Review

Susquehanna International Group sold out of Adial Pharmaceuticals (ADIL) in Q1 2026, closing a stake of 483 shares — an estimated $2.66K sold.

Susquehanna International Group first reported a position in ADIL in Q1 2020 and held it in 9 quarters. The position peaked at $133K in Q2 2022. 15 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Susquehanna International Group reported no remaining Adial Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 483 Adial Pharmaceuticals shares in Q1 2026, an estimated $2.66K.
  • Susquehanna International Group first reported a position in Adial Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Susquehanna International Group's Adial Pharmaceuticals position peaked at $133K in Q2 2022.
  • 15 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.